These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9840212)

  • 1. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
    Adams MH; Poynor WJ; Garnett WR; Karnes HT; Ferry JJ; Ryan KK; Sarkar MA
    Biopharm Drug Dispos; 1998 Nov; 19(8):501-15. PubMed ID: 9840212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
    Andersen V; Sonne J; Larsen S
    Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.
    Greenblatt DJ; Allen MD; MacLaughlin DS; Huffman DH; Harmatz JS; Shader RI
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):159-79. PubMed ID: 20218012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced hepatic drug clearance in patients with cystic fibrosis.
    Kearns GL; Mallory GB; Crom WR; Evans WE
    J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of neurotrauma on hepatic drug clearance.
    Boucher BA; Kuhl DA; Fabian TC; Robertson JT
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):487-97. PubMed ID: 1934861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hepatic disease on the disposition of moricizine in humans.
    Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M
    Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers.
    Fleishaker JC; Andreadis NA; Welshman IR; Wright CE
    J Clin Pharmacol; 1989 Feb; 29(2):162-7. PubMed ID: 2715373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
    Razak TA; McNeil JJ; Sewell RB; Drummer OH; Smallwood RA; Conway EL; Louis WJ
    Clin Pharmacol Ther; 1990 Apr; 47(4):463-9. PubMed ID: 2328554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of experimental hemorrhagic shock on hepatic drug elimination.
    DiPiro JT; Hooker KD; Sherman JC; Gaines MG; Wynn JJ
    Crit Care Med; 1992 Jun; 20(6):810-5. PubMed ID: 1597036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
    Avram MJ; Krejcie TC; Niemann CU; Klein C; Gentry WB; Shanks CA; Henthorn TK
    Anesthesiology; 1997 Dec; 87(6):1381-93. PubMed ID: 9416724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
    Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of zileuton on antipyrine and indocyanine green disposition.
    St Peter JV; Braeckman RA; Granneman GR; Locke CS; Cavanaugh JH; Awni WM
    Clin Pharmacol Ther; 1995 Mar; 57(3):299-308. PubMed ID: 7697947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
    Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
    J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
    Saudek F; Morávek J; Modr Z
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
    Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
    Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
    Eldon MA; Luecker PW; MacGee J; Ritschel WA
    J Clin Pharmacol; 1987 Mar; 27(3):226-32. PubMed ID: 3680579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.